Movement Alert｜Duality Biotherapeutics-B Rises 6.31% in Regular Trading, ADC Sector Breakthroughs and STAR Market IPO Filing Continue to Drive Momentum

Market Focus09:41

On July 3, Duality Biotherapeutics-B rose 6.31% in regular trading, trading at HKD 216.8/share, with turnover of approximately HKD 106 million. This follows a 15.01% surge the prior session.

On the news front, the domestic ADC (antibody-drug conjugate) sector has seen concentrated breakthroughs recently, with the world's first bispecific antibody ADC receiving marketing approval, highlighting the leading edge of Chinese biotech firms. Concurrently, the company's STAR Market IPO application has been accepted by the Shanghai Stock Exchange, with plans to raise RMB 4.1 billion for new drug development, establishing a dual-capital-market platform strategy.

Within the Biotechnology sector, strong linkage effects persist. Among individual stocks, 3SBIO up 5.46%, Remegen up 5.62%, SKB Bio up 3.89%, Akeso up 3.06%, and Innovent Bio up 2.75%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160793891?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 09:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160793891","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Duality Biotherapeutics-B Rises 6.31% in Regular Trading, ADC Sector Breakthroughs and STAR Market IPO Filing Continue to Drive Momentum","media":"Market Focus","content":"<p><p>On July 3, Duality Biotherapeutics-B rose 6.31% in regular trading, trading at HKD 216.8/share, with turnover of approximately HKD 106 million. This follows a 15.01% surge the prior session.</p><p>On the news front, the domestic ADC (antibody-drug conjugate) sector has seen concentrated breakthroughs recently, with the world's first bispecific antibody ADC receiving marketing approval, highlighting the leading edge of Chinese biotech firms. Concurrently, the company's STAR Market IPO application has been accepted by the Shanghai Stock Exchange, with plans to raise RMB 4.1 billion for new drug development, establishing a dual-capital-market platform strategy.</p><p>Within the Biotechnology sector, strong linkage effects persist. Among individual stocks, 3SBIO up 5.46%, Remegen up 5.62%, SKB Bio up 3.89%, Akeso up 3.06%, and Innovent Bio up 2.75%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Duality Biotherapeutics-B Rises 6.31% in Regular Trading, ADC Sector Breakthroughs and STAR Market IPO Filing Continue to Drive Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Duality Biotherapeutics-B Rises 6.31% in Regular Trading, ADC Sector Breakthroughs and STAR Market IPO Filing Continue to Drive Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-03 09:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 3, Duality Biotherapeutics-B rose 6.31% in regular trading, trading at HKD 216.8/share, with turnover of approximately HKD 106 million. This follows a 15.01% surge the prior session.</p><p>On the news front, the domestic ADC (antibody-drug conjugate) sector has seen concentrated breakthroughs recently, with the world's first bispecific antibody ADC receiving marketing approval, highlighting the leading edge of Chinese biotech firms. Concurrently, the company's STAR Market IPO application has been accepted by the Shanghai Stock Exchange, with plans to raise RMB 4.1 billion for new drug development, establishing a dual-capital-market platform strategy.</p><p>Within the Biotechnology sector, strong linkage effects persist. Among individual stocks, 3SBIO up 5.46%, Remegen up 5.62%, SKB Bio up 3.89%, Akeso up 3.06%, and Innovent Bio up 2.75%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1160793891","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160793891","pubTimestamp":1783042890,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 3, Duality Biotherapeutics-B rose 6.31% in regular trading, trading at HKD 216.8/share, with turnover of approximately HKD 106 million. This follows a 15.01% surge the prior session.On the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"动静提示|Duality Biotherapeutics-B常规交易上涨6.31%，ADC板块突破和科创板IPO备案继续推动动能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On July 3, Duality Biotherapeutics-B rose 6.31% in regular trading, trading at HKD 216.8/share, with turnover of approximately HKD 106 million. This follows a 15.01% surge the prior session.On the news front, the domestic ADC (antibody-drug conjugate) sector has seen concentrated breakthroughs recently, with the world's first bispecific antibody ADC receiving marketing approval, highlighting the leading edge of Chinese biotech firms. Concurrently, the company's STAR Market IPO application has been accepted by the Shanghai Stock Exchange, with plans to raise RMB 4.1 billion for new drug development, establishing a dual-capital-market platform strategy.Within the Biotechnology sector, strong linkage effects persist. Among individual stocks, 3SBIO up 5.46%, Remegen up 5.62%, SKB Bio up 3.89%, Akeso up 3.06%, and Innovent Bio up 2.75%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160793891","isCrawlerRequest":true}